2023 World Conference on Lung Cancer (Posters)-EP11.03. Clinical Impact of Immune Checkpoint Inhibitors Following Platinum Chemotherapy in Advanced or Metastatic Non-small Cell Lung Cancer Patients

EP11.03. Clinical Impact of Immune Checkpoint Inhibitors Following Platinum Chemotherapy in Advanced or Metastatic Non-small Cell Lung Cancer Patients - PDF(Slides)

Back to course

Pdf Summary

Lung cancer is a leading cause of morbidity and mortality worldwide, with increasing incidence rates in Korea. The introduction of national lung cancer screening in 2018 is expected to further increase these rates. The development of immune checkpoint inhibitors (ICIs) has significantly improved the treatment of lung cancer, leading to increased overall survival and progression-free survival compared to chemotherapy. In 2015, the FDA approved nivolumab and pembrolizumab, the first PD-1 targeting monoclonal antibodies, for advanced NSCLC. In Korea, ICIs have been available as second-line treatment since 2016.<br /><br />This study analyzed the difference in medical expenses and the impact on prognosis in patients with advanced or metastatic NSCLC receiving ICIs. Data from the Korean National Health Insurance Service population were used, including patients diagnosed with stage IIIB or IV NSCLC who received palliative chemotherapy from 2013 to 2020. The study evaluated overall mortality, progression-free survival, and medical expenditure.<br /><br />The results showed that subsequent ICIs after platinum-based cytotoxic chemotherapy improved overall survival rates among advanced NSCLC patients. However, ICI treatment was associated with higher medical expenses. Patients receiving ICIs had a lower risk of disease progression. Median overall survival and progression-free survival were longer in the targeted therapy group compared to the cytotoxic therapy group, and shorter in the ICI groups. The introduction of ICIs was also associated with an increasing trend in medical expenses.<br /><br />In conclusion, subsequent ICIs after platinum-based cytotoxic chemotherapy have shown improved overall survival in advanced NSCLC patients. However, the increased medical expenses associated with ICI treatment require further research to identify patients who may benefit most from this treatment.

Asset Subtitle

Sang Chul Lee

Meta Tag

Speaker Sang Chul Lee

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

lung cancer

morbidity

mortality

incidence rates

lung cancer screening

immune checkpoint inhibitors

overall survival

progression-free survival

medical expenses

advanced NSCLC